ArticleACS omega2024
TCellPredX: A Novel Approach for Accurate Prediction of Hepatitis C Virus Linear T Cell Epitopes.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Improving B-cell Linear Epitope PredictionCurrent drug targets · 2026Article
- METFAN: Multisource Enhanced Therapeutic Peptide Function Prediction via Adapter Network.ACS omega · 2025Article
- DeepBBMC biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C Virus (HCV) is a bloodborne RNA virus that leads to severe liver diseases, and currently, no effective prophylactic biologics are available to prevent its transmission. The prevention of HCV is closely related to the major histocompatibility complex (MHC). Linear antigenic peptides of HCV, known as T cell epitopes (TCEs), are crucial in the presentation process by MHC molecules to T cells, playing a key role in immune responses. Therefore, the rapid and accurate identification of these TCE-HCVs is essential for advancing vaccine development. Herein, we propose TCellPredX, a novel integrated predictor for TCE-HCV identification. TCellPredX leverages five distinct feature encoding schemes, including local and global sequence encodings, composition-transition-distribution descriptors, physicochemical properties, and embeddings from two protein language models, which are processed through 12 machine learning algorithms. Our results indicate that feature fusion significantly enhances predictive accuracy. Moreover, the maximal relevance minimal redundancy feature selection method is particularly effective in isolating informative features, ensuring the model's use of the most informative data. Additionally, ensemble models, especially when combined with an averaged voting strategy, demonstrate superior stability and accuracy compared to individual classifiers, effectively reducing noise and enhancing model robustness. TCellPredX achieves notable accuracies of 0.900 and 0.897 in 10-fold cross-validation and independent test, respectively. Furthermore, TCellPredX's high accuracy is validated on experimentally verified peptide sequences documented for their potential benefits in vaccine development. Overall, TCellPredX can offer a robust tool for the precise identification of TCE-HCV, potentially serving as a cornerstone for future epitope research and advancing HCV vaccines development.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.